Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 99.73% | 46.92% | -638.63% | 109.92% | -596.19% |
| Total Depreciation and Amortization | 0.00% | 26.67% | 10.21% | -45.15% | 13.75% |
| Total Amortization of Deferred Charges | 3.70% | -6.90% | 0.00% | 11.54% | -3.70% |
| Total Other Non-Cash Items | -119.79% | -77.55% | 376.00% | -117.46% | 1,315.01% |
| Change in Net Operating Assets | 303.31% | -145.54% | 17,417.39% | -101.35% | 116.76% |
| Cash from Operations | 205.36% | -213.80% | 694.66% | -122.05% | 143.42% |
| Capital Expenditure | -- | 100.00% | -- | -- | 75.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -- | -- | -4,272.46% |
| Total Debt Issued | -200.90% | 123.04% | -199.79% | 551.35% | -85.17% |
| Total Debt Repaid | -644.18% | 0.22% | -0.22% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -34.07% | -81.56% |
| Cash from Financing | -650.57% | 113.92% | -372.78% | -82.33% | 202.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.70% | -27.06% | -255.24% | -86.87% | 674.34% |